Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
The article highlights recent insider transactions for three penny stocks: Grove Collaborative Holdings, Fresh Tracks Therapeutics, and Monopar Therapeutics. Insider buying can indicate confidence in the company's prospects.
June 03, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Grove Collaborative Holdings' President and CEO Jeffrey Michael Yurcisin bought 17,100 shares at $1.63 each, totaling around $27,951. The company recently posted a narrower-than-expected quarterly loss.
Insider buying by the CEO, coupled with a narrower-than-expected quarterly loss, suggests confidence in the company's future, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Monopar Therapeutics' COO Andrew Cittadine acquired 36,000 shares at $0.64 each, totaling around $23,051. The company's CFO Kim R. Tsuchimoto is retiring.
Insider buying by the COO indicates confidence in the company's future, which may positively impact the stock price in the short term despite the CFO's retirement.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70